Payment overview · 2025
General Payments
$231.83
6 reported records · 4 companies
Healthcare provider profile · identity verified
Priya Vasdev, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BOWIE, MD · NPI 1942221197
Verified facts
What the public records show
CMS Open Payments records show Priya Vasdev, M.D. received $231.83 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 62.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $145.72 | 62.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.73 | 16.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.93 | 10.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.45 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $231.83 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $145.72 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
347 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 347 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 47 |
| Mirtazapine | Mirtazapine | 198 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 46 |
| Gabapentin | Gabapentin | 167 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 33 |
| Furosemide | Furosemide | 141 | 37 |
| Trazodone Hcl | Trazodone Hcl | 114 | 24 |
| Losartan Potassium | Losartan Potassium | 113 | 31 |
| Famotidine | Famotidine | 101 | 28 |
| Metformin Hcl | Metformin Hcl | 101 | 28 |
| Sertraline Hcl | Sertraline Hcl | 101 | 21 |
| Clonazepam | Clonazepam | 97 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 25 |
| Tramadol Hcl | Tramadol Hcl | 90 | 27 |
| Potassium Chloride | Potassium Chloride | 89 | 26 |
| Lorazepam | Lorazepam | 86 | 16 |
| Lisinopril | Lisinopril | 84 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 22 |
| Carvedilol | Carvedilol | 75 | 18 |
| Omeprazole | Omeprazole | 73 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 13 |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | 11 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 28 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 20 |
| Risperidone | Risperidone | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 20 |
| Simvastatin | Simvastatin | 42 | 12 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | 23 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Prednisone | Prednisone | 35 | 14 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 15 |
| Midodrine Hcl | Midodrine Hcl | 27 | 13 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Pradaxa | Dabigatran Etexilate Mesylate | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Budesonide Dr | Budesonide | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | 11 |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Klayesta | Nystatin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Klor-Con | Potassium Chloride | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $231.83 · 6 records | Otsuka America Pharmaceutical, Inc. | EVENITY, REXULTI, VYNDAQEL, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error